PENG vs Intra-articular Injection for Hip Arthroscopy
Launched by BEZMIALEM VAKIF UNIVERSITY · Jan 5, 2021
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating two methods for managing pain after hip arthroscopy surgery, a common procedure for treating hip problems. The trial compares a newer pain relief technique called the PENG block with a traditional method of injecting pain medication directly into the hip joint. The aim is to find out which method works better for controlling pain after surgery, helping patients recover more comfortably and quickly without relying heavily on opioids.
To participate in this trial, individuals must be between the ages of 18 and 75, have an acceptable body weight, and be scheduled for elective hip arthroscopy. They should also be able to understand the study and provide consent to participate. Participants will receive one of the pain management techniques during their surgery and will be monitored for their pain levels afterwards. It’s important to note that those with certain health conditions, such as severe kidney issues or those requiring ongoing opioid use, will not be eligible for this study. This research could help improve pain management strategies for future hip surgery patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Association of Anesthesiologists (ASA) physical status I - III
- • BMI 20 to 35 kg / m2
- • Patients scheduled for elective hip arthroscopy
- • Able to provide informed consent.
- Exclusion Criteria:
- • Patients who refuse to participate in the study,
- • Coagulopathy,
- • Sepsis,
- • Hepatic or renal insufficiency,
- • Pregnancy
- • Allergy to local anesthetic drugs,
- • Chronic pain condition requiring opioid intake at home,
- • BMI above 40.
- • History of psychiatric diseases needing treatment.
- • Failure of nerve block
- • Substance abuse history
- • Hip revision surgery
- • Underlying neurologic disorder affecting pain perception.
- • Angina, heart attack, heart failure
- • Kidney or hepatic insufficiency
- • Stroke
- • Gastrintestinal bleeding history
About Bezmialem Vakif University
Bezmialem Vakif University is a prominent academic institution based in Istanbul, Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct innovative research that aims to improve patient outcomes and enhance therapeutic strategies. Bezmialem Vakif University is committed to adhering to rigorous ethical standards and regulatory guidelines, ensuring the integrity and reliability of its clinical trials while fostering collaboration with global research communities. Through its initiatives, the university seeks to contribute significantly to the field of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Yeşiltaş
Principal Investigator
Bezmialem Vakif University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials